Efeitos do uso de incretinomiméticos em mulheres com sobrepeso/obesidade em planejamento familiar: uma revisão sistemática
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Resumo
Objetivo: Avaliar a eficácia e a segurança do uso dos agonistas do GLP-1 (GLP-1A) em mulheres com sobrepeso/obesidade que planejam uma gestação. Métodos: Trata-se de uma revisão sistemática, cujos ensaios clínicos randomizados (ECRs) foram obtidos nas bases de dados National Library of Medicine, Biblioteca Virtual em Saúde e Ovid Cochrane Central Register of Controlled Trials, triados com os softwares Rayyan e avaliados pelo esquema proposto por Jadad et al. (1996). Resultados: Os ECRs que constituíram a amostra abordam desfechos metabólicos/reprodutivos acerca do uso de GLP-1A em mulheres com sobrepeso/obesidade no período que antecedeu a gestação. Apenas três estudos abordaram as reações adversas obstétricas. Nestes estudos, os GLP-1A foram descritos como seguros e associados a menor frequência de eventos adversos. Além disso, o uso de agonistas do GLP-1 demonstrou eficácia maior quando associada a outros medicamentos utilizados para melhora das funções metabólicas e reprodutivas nessa população. Considerações finais: Apesar da variedade terapêutica e dos indiscutíveis benefícios metabólicos e reprodutivos da terapia com GLP-1A em mulheres com sobrepeso/obesidade em planejamento familiar, o número de ECR que abordam os desfechos de segurança obstétricos é reduzido, e em sua maioria, possuem uma amostra pequena, mantendo o impasse na implementação desta terapia.
##plugins.themes.bootstrap3.article.details##
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Referências
2. BAYS HE, et al. Obesity algorithm eBook, presented by the Obesity Medicine Association, 2021.
3. BELL GI, et al. Exon duplication and divergence in the human preproglucagon gene. Nature, 1983; 304 (5924): 368-371.
4. DAO K, et al. Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicenter, observational, prospective cohort study based on the databases of six Teratology Information Services. BMJ open, 2024; 14(4): e083550.
5. ELKIND-HIRSCH KE, et al. Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight/obese women with recent gestational diabetes: a double-blind, randomized, placebo-controlled study. Journal of Diabetes and its Complications, 2020; 34(4): 107548.
6. FERJAN S, et al. Dipeptidyl peptidase-4 inhibitor sitagliptin prevented weight regain in obese women with polycystic ovary syndrome previously treated with liraglutide: a pilot randomized study. Metabolic syndrome and related disorders, 2017; 15(10): 515-520.
7. FOGHSGAARD S, et al. Liraglutide treatment for the prevention of glucose tolerance deterioration in women with prior gestational diabetes mellitus: a 52‐week randomized controlled clinical trial. Diabetes, Obesity and Metabolism, 2024; 26(1):201-214.
8. GAMBINERI A, et al. “Female infertility: which role for obesity?”.International journal of obesity supplements, 2019; 9(1): 65-72.
9. GARVEY W, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocrine Practice, 2016; 22: 1-203.
10. GBD 2019 RISK FACTOR COLLABORATORS. Global Burden of 87 Risk Factors in 204 Countries and Territories, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet, 2020; 396: 1223–1249.
11. IMBROANE MR, et al. Preconception GLP-1 Receptor Agonist Use Associated with Decreased Risk for Adverse Obstetric Outcomes. American Journal of Obstetrics and Gynecology, 2025.
12. JADAD AR, et al. “Assessing the quality of reports of randomized clinical trials: is blinding necessary?”. Control Clin Trials, 1996; 17: 1-12.
13. JENSEN MD, et al. 2013 AHA/ACC/TOSS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation, 2014; 129(25): S102-S138.
14. JENSTERLE M, et al. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective. Human reproduction update, 2019; 25(4): 504-517.
15. JUNGHEIM ES, MOLEY KH. Current knowledge of obesity's effects in the pre-and periconceptional periods and avenues for future research. American journal of obstetrics and gynecology,2010; 203(6): 525-530.
16. KASUM M, et al. The role of female obesity on in vitro fertilization outcomes. Gynecological endocrinology, 2018; 34 (3): 184-188.
17. LI R, et al. Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT. Archives of Gynecology and Obstetrics, 2022; 306(5): 1711-1721.
18. LIU X, et al. Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome. Clinical endocrinology, 2017; 8 (6):767-774.
19. MODARRES SZ, et al. Comparative evaluation of metformin &sitaformin in classic PCOS patients undergoing intracytoplasmic sperm injection: A randomized controlled pilot study. Indian Journal of Medical Research, 2023; 157(1): 66-73.
20. OUZZAN M, et al. Rayyan—a web and mobile app for systematic reviews. Systematic reviews, 2016; 5:1-10.
21. PALMA JCP, et al. Comparative treatment between sitagliptin vs. metformin, alone or in combination, in patients with polycystic ovary syndrome. A clinical entity at high risk for developing diabetes mellitus and gestational diabetes: A pilot study. Revista Medica del Hospital General de Mexico,2018; 81(1): 15-26.
22. NAUCK MA, MEIER JJ. Incretin hormones: Their role in health and disease.Diabetes, Obesity and Metabolism, 2018; 20: 5-21.
23. NISHIYAMA Y, et al. Incretins modulate progesterone biosynthesis by regulating bone morphogenetic protein activity in rat granulosa cells. The Journal of Steroid Biochemistry and Molecular Biology, 2018; 178: 82-88.
24. NOMMSEN-RIVERS L, et al. Feasibility and acceptability of metformin to augment low milk supply: a pilot randomized controlled trial. Journal of Human Lactation, 2019; 35(2): 261-271.
25. OKUNOGBE A, et al.Economic Impacts of Overweight and Obesity.2nd Edition with Estimates for 161 Countries. World Obesity Federation, 2022.
26. RAMLAU-HANSEN CH, et al. Subfecundity in overweight and obese couples. Human reproduction, 2007; 22 (6): 1634-1637.
27. SALAMUN V, et al. Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. European journal of endocrinology, 2018; 179 (1): 1-11.
28. VAN DER STEEG JW, et al. Obesity affects spontaneous pregnancy chances in subfertile, ovulatory women. Human reproduction, 2008; 23(2): 324-328.
29. YUMUK V, et al. European guidelines for obesity management in adults. Obesity facts, 2015; 8(6): 402-424.
30. ZHANG S. Effect of liraglutide combined with clomiphene on serum sex hormone levels and natural conception rate in obese women with polycystic ovary syndrome. Chinese Journal of Primary Medicine and Pharmacy, 2020.